Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial

RCT (n=241) found that those given bevacizumab plus mFOLFOX6 had improved objective response rates (54.5% vs 36.7%, p<0.01), progression free survival (9.5 vs 5.6 months, p<0.01) and overall survival (25.7 vs 20.5 months, p=0.03) vs those given mFOLFOX6 alone.

Journal of Clinical Oncology